0001683168-26-001190
SEC filingCannabis Bioscience International Holdings, Inc. (CBIH) reported a net loss of $117K for Q2 2026 (period ending November 30, 2025). Revenue for the quarter was $53K, generating a gross profit of $43K (gross margin of 81.1%). However, total operating expenses of $139K resulted in an operating loss of $96K. Other expenses, primarily interest of $18K, contributed to the net loss. The company's balance sheet shows total assets of $22K, significantly outweighed by total liabilities of $1.4M, resulting in a stockholders' deficiency of $1.4M. Cash flow from operations was negative $109K, partially offset by $96K in financing activities from a related-party loan, leading to a net decrease in cash of $13K and an ending cash balance of $13K. The company continues to operate with negative equity and relies on financing activities to fund operations.
Cannabis Bioscience International Holdings, Inc. (CBIH) reported financial results for Q2 2026 (period ending November 30, 2025). The company generated $53K in revenue, with a cost of revenue of $10K, resulting in a gross profit of $43K. Total operating expenses were $139K, comprising general and administrative ($31K), contract labor ($36K), professional fees ($52K), officer compensation ($8K), rent and lease ($11K), and travel ($62). This led to an operating loss of $96K. Other expenses totaled $21K, including note discount expense ($3K) and interest ($18K), resulting in a net loss of $117K. Basic and diluted loss per share were both -$0. The company had average common stock outstanding of 11.63 billion shares.
Revenue for the quarter was $53K. The document and XBRL data do not provide a segment breakdown, geographic mix, or specific growth drivers for the revenue. No prior period revenue figure is provided in the source data for Q2 2026, preventing a quarter-over-quarter comparison. The analysis is limited to the absolute revenue figure reported for the period.
The company achieved a gross margin of 81.1% ($43K gross profit / $53K revenue). However, high operating expenses led to a significant operating loss margin of -181.1% (-$96K operating loss / $53K revenue). The cost structure shows professional fees ($52K) and contract labor ($36K) as the largest operating expense components. The net loss margin was -220.8% (-$117K net loss / $53K revenue).
Net cash used in operating activities was $109K, driven by the net loss of $117K, partially offset by increases in accounts payable and accrued expenses ($116K) and related party payable ($21K), and a decrease in accounts receivable ($15K). Cash flow from financing activities provided $96K, primarily from a $105K related-party loan, offset by a $9K payment on notes payable. This resulted in a net decrease in cash of $13K, with an ending cash balance of $13K. The balance sheet shows total assets of $22K, including $22K in total current assets (primarily $22K in accounts receivable). Total liabilities are $1.4M, including $1.1M in current liabilities (notably $793K in related-party payables and $159K in accounts payable) and $250K in long-term SBA loans. Stockholders' deficiency is $1.4M, consisting of $4.7M in additional paid-in capital and a $6.1M accumulated deficit.
The provided document content and XBRL data for the Q2 2026 10-Q filing do not contain any forward-looking statements, management guidance, strategic priorities, or specific risk factors. Therefore, no outlook information can be reported based on the source material provided.